Biotech

Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...

This was a huge week for the marijuana industry: Canada became the second country in the world to legalize cannabis for recreational uses. “October 17 was set as the first day for recreational sales. Some people in the industry wanted an earlier date, but at least companies can now make plans...

Achaogen Inc (NASDAQ: AKAO) shares have been rangebound between $10 and $14 since late last year, with a mixed FDA panel vote on its antibiotic treatment candidate plazomicin in early May stifling any potential rally. A Plazomicin Primer Plazomicin is Achaogen's lead product candidate. It is a...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 21) Aerie Pharmaceuticals Inc (NASDAQ: AERI) FibroGen Inc (NASDAQ: FGEN) Heron Therapeutics Inc (NASDAQ: HRTX)(announced its pain treatment candidate HTX...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 20) Agios Pharmaceuticals Inc (NASDAQ: AGIO)(announced initiation of Phase 3 ACTIVATE study, which evaluated its AG-348 in patients with Pyruvate kinase...

Caladrius Biosciences Inc (NASDAQ: CLBS) shares were trading sharply higher for a second straight session Wednesday after the FDA granted a special status for its CD34+ cell therapy. What Happened Caladrius Biosciences announced Tuesday ahead of the market open that the FDA granted...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO) Array Biopharma Inc (NASDAQ: ARRY) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) AtriCure Inc. (NASDAQ: ATRC)...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouraging results from the first three patients treated with the company’s microdystrophin gene therapy program for Duchenne Muscular Dystrophy (DMD), sending the stock soaring higher by 40 percent Tuesday and prompting positive...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares, halted shortly before Tuesday's open, opened higher by more than 50 percent. What Happened Sarepta released Phase 1/2 data on its microdystrophin gene therapy for Duchenne muscular dystrophy, or DMD, which showed robust levels of microdystrophin...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) lost a sell-side bull Tuesday, with a B. Riley FBR analyst praising the company's pipeline but concluding the biotech's positives are priced into the stock. The Analyst B. Riley FBR's Madhu Kumar downgraded Deciphera from Buy to Neutral. The...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (announced full enrolment of patients in a Phase 1 study of ARO-AAT...

As Scholar Rock Holding Corp (NASDAQ: SRRK)’s IPO quiet period expired Monday, four analysts came out with bullish recommendations on the stock. Here’s what one of them had to say. The Rating BMO Capital Markets analyst Do Kim initiated coverage with an Outperform rating and $31...

Below is a list of notable corporate events for the week beginning June 18. Note, this list is not comprehensive and all dates are subject to change. All times are ET. Monday Conferences Blockchain Economic Forum June 16-19 FDA/Biotech Valeant Pharmaceuticals International, Inc (NYSE: VRX) PDUFA...

Verastem Inc (NASDAQ: VSTM) shares gained 20 percent Monday morning and traded above the $7 per share mark for the first time since 2015 in reaction to an encouraging presentation delivered over the weekend. What Happened Versatem presented encouraging results from its lead candidate...

Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements.  Here are a few catalytic events in the upcoming week that should be on the radar of every...